Shares of Dianthus Therapeutics Inc. (DNTH) surged 7.86% on Thursday morning, following the company's third-quarter earnings report that beat analysts' expectations on the revenue front.
The biotechnology firm reported a quarterly adjusted loss of $0.72 per share, wider than the expected loss of $0.59 per share. However, revenue rose a staggering 135.1% year-over-year to $2.17 million, significantly higher than the consensus estimate of $648,500.
Despite the larger-than-expected loss, investors seemed to be encouraged by Dianthus Therapeutics' strong revenue growth, driving the stock higher. The company's shares have gained 182.8% so far this year, reflecting the market's confidence in its prospects.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.